Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Park Avenue Securities LLC

Park Avenue Securities LLC cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 36.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,945 shares of the medical equipment provider’s stock after selling 1,127 shares during the period. Park Avenue Securities LLC’s holdings in Lantheus were worth $213,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of LNTH. Daiwa Securities Group Inc. purchased a new stake in shares of Lantheus in the 1st quarter valued at about $1,269,000. Nordea Investment Management AB boosted its holdings in shares of Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock valued at $2,932,000 after acquiring an additional 14,147 shares during the period. Hancock Whitney Corp grew its position in shares of Lantheus by 265.6% during the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after acquiring an additional 14,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Lantheus in the 2nd quarter valued at $290,000. Finally, Pitcairn Co. raised its position in Lantheus by 117.0% in the 1st quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after purchasing an additional 4,509 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $110.72 on Tuesday. The firm’s fifty day simple moving average is $104.44 and its 200-day simple moving average is $89.85. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The stock has a market cap of $7.67 billion, a PE ratio of 16.90 and a beta of 0.50. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter in the previous year, the company posted $1.40 earnings per share. The company’s quarterly revenue was up 22.5% compared to the same quarter last year. Analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the sale, the director now owns 454,923 shares of the company’s stock, valued at approximately $43,445,146.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares in the company, valued at $9,540,682.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the sale, the director now owns 454,923 shares in the company, valued at approximately $43,445,146.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,981 shares of company stock valued at $2,689,156. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

LNTH has been the topic of a number of recent research reports. Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Leerink Partners upped their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. JMP Securities lowered their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. B. Riley upped their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Finally, Redburn Atlantic began coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.